Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
Peking University First Hospital
Peking University First Hospital
Fudan University
Fudan University
The Netherlands Cancer Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ottawa Hospital Research Institute
National Taiwan University Hospital
Fudan University
RenJi Hospital
Xijing Hospital
Shandong Cancer Hospital and Institute
Sun Yat-sen University
Shandong Cancer Hospital and Institute
ChineseAMS
Nanjing Luye Sike Pharmaceutical Co., Ltd.
Harbin Medical University
National Taiwan University Hospital
Far Eastern Memorial Hospital
Academy Military Medical Science, China